EYSUVIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eysuvis, and when can generic versions of Eysuvis launch?
Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug.
This drug has eighty-four patent family members in twelve countries.
The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis
A generic version of EYSUVIS was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EYSUVIS?
- What are the global sales for EYSUVIS?
- What is Average Wholesale Price for EYSUVIS?
Summary for EYSUVIS
| International Patents: | 84 |
| US Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 65 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,390 |
| Drug Prices: | Drug price information for EYSUVIS |
| What excipients (inactive ingredients) are in EYSUVIS? | EYSUVIS excipients list |
| DailyMed Link: | EYSUVIS at DailyMed |
Recent Clinical Trials for EYSUVIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Price Vision Group | Phase 4 |
| Kala Pharmaceuticals, Inc. | Phase 4 |
Pharmacology for EYSUVIS
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for EYSUVIS
EYSUVIS is protected by sixteen US patents.
Patents protecting EYSUVIS
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EYSUVIS
See the table below for patents covering EYSUVIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 742004 | Pharmaceutical nanoparticles showing improved mucosal transport | ⤷ Sign Up |
| European Patent Office | 2844223 | NANOPARTICULES PHARMACEUTIQUES À TRANSPORT MUCOSAL AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) | ⤷ Sign Up |
| China | 111700878 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
